Kodiak Sciences (KOD) Competitors

Kodiak Sciences (NASDAQ:KOD) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Which has preferable earnings and valuation, KOD or NUVB?

Nuvation Bio has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$260.49M	-$3.63	-0.96
Nuvation Bio	$10.96M	63.20	-$75.80M	-$2.35	-0.87

Does the MarketBeat Community believe in KOD or NUVB?

Nuvation Bio received 38 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 81.43% of users gave Nuvation Bio an outperform vote while only 27.14% of users gave Kodiak Sciences an outperform vote.

Company	Underperform	Outperform
Kodiak Sciences	Outperform Votes 19 27.14%	Underperform Votes 51 72.86%
Nuvation Bio	Outperform Votes 57 81.43%	Underperform Votes 13 18.57%

Does the media refer more to KOD or NUVB?

In the previous week, Kodiak Sciences had 1 more articles in the media than Nuvation Bio. MarketBeat recorded 8 mentions for Kodiak Sciences and 7 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 1.03 beat Kodiak Sciences' score of 0.13 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvation Bio	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, KOD or NUVB?

Kodiak Sciences has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.

Do insiders and institutionals have more ownership in KOD or NUVB?

89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 45.3% of Kodiak Sciences shares are held by company insiders. Comparatively, 29.9% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is KOD or NUVB more profitable?

Nuvation Bio's return on equity of -21.89% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-84.52%	-45.40%
Nuvation Bio	N/A	-21.89%	-17.86%

Do analysts rate KOD or NUVB?

Kodiak Sciences currently has a consensus price target of $9.00, indicating a potential upside of 157.51%. Nuvation Bio has a consensus price target of $7.83, indicating a potential upside of 284.93%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvation Bio	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Summary

Nuvation Bio beats Kodiak Sciences on 13 of the 17 factors compared between the two stocks.